Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.53 |
| ▸ | F10 | P00742 | 1/20 | 0.53 |
| ▸ | PRMT1 | Q99873 | 7/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.48 |
| ▸ | PLG | P00747 | 2/20 | 0.48 |
| ▸ | PLAU | P00749 | 2/20 | 0.48 |
| ▸ | KLK1 | P06870 | 2/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | PRMT7 | Q9NVM4 | 2/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TOP1 | P11387 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7764733 | 0.98 | F2 (0.51) | F2F10PRMT1PRSS1PLG | |
| Hydrochloric Acid SCHEMBL2035460 | 0.98 | F2 (0.51) | F2F10PRMT1PRSS1PLG | |
| SCHEMBL3368604 | 0.91 | MEN1 (0.55) | F2F10PRSS1PLGPLAU | |
| Hydrochloric Acid SCHEMBL29213647 | 0.89 | KMT2A (0.53) | F2F10PRSS1PLGPLAU | |
| SCHEMBL1819244 | 0.88 | TTR (0.54) | F2F10PRMT1PRSS1PLG | |
| SCHEMBL12348359 | 0.83 | PRMT1 (0.58) | F2F10PRMT1PRSS1PLG | |
| Hydrochloric Acid SCHEMBL7766605 | 0.81 | PRMT1 (0.56) | F2F10PRMT1PRSS1PLG | |
| Hydrochloric Acid SCHEMBL16974018 | 0.80 | BLM (0.40) | F2F10PRSS1PLGPLAU | |
| SCHEMBL13204606 | 0.77 | PRMT1 (0.45) | F2F10PRMT1PRSS1PLG | |
| SCHEMBL21926432 | 0.76 | ALOX5 (0.56) | F2F10PRSS1PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| EP-1651211-A4 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX INC (US) | 2006-11-22 | — | — | EP | claimed |
| CN-1829509-A | Pharmaceutical composition for treating tumors | COMBINATORX INC (US) | 2006-09-06 | — | — | CN | claimed |
| EP-1651211-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1545544-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | claimed |
| WO-2005020913-A2 | FORMULATIONS, CONJUGATES, AND COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | claimed |
| WO-2005011572-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-02-10 | — | — | WO | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | claimed |
| US-11839140-B2 | Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS | UDC IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11839140-B2 | Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS | UDC IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20230026258-A1 | Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS | UDC IRELAND LTD (IE) | 2023-01-26 | — | — | US | disclosed |
| US-20210126207-A1 | Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS | UDC IRELAND LTD (IE) | 2021-04-29 | — | — | US | disclosed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004002430-A2 | COMBINATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | COMBINATORX INCORPORATED (US) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | ABCB1, SLCO1B3, SLCO1B1 | F2 4176/4885F10 4333/4885PRMT1 2728/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | F2 2085/4885F10 2519/4885PRMT1 2584/4885 |
| US-20230026258-A1 | Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS | OCIAD1, OCIAD2, DRD2 | F2 2682/4885F10 2541/4885PRMT1 3899/4885 |
| US-11839140-B2 | Metal complexes comprising diazabenzmidazolocarbene ligands and the use thereof in OLEDS | OCIAD1, OCIAD2, DRD2 | F2 2682/4885F10 2541/4885PRMT1 3899/4885 |
| US-20210126207-A1 | Metal Complexes Comprising Diazabenzmidazolocarbene Ligands and the Use Thereof in OLEDS | OCIAD1, OCIAD2, DRD2 | F2 2682/4885F10 2541/4885PRMT1 3899/4885 |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | TYMP, DPYD, DHFR | F2 3907/4885F10 3617/4885PRMT1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.